Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XIAP | P98170 | 3/20 | 0.60 |
| ▸ | ELANE | P08246 | 9/20 | 0.44 |
| ▸ | CAPN1 | P07384 | 4/20 | 0.43 |
| ▸ | CTSB | P07858 | 1/20 | 0.43 |
| ▸ | MLX | Q9UH92 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29497357 | 0.92 | XIAP (0.71) | XIAPELANEMLXPOLB | |
| SCHEMBL13697495 | 0.92 | XIAP (0.71) | XIAPELANEMLXPOLB | |
| SCHEMBL13379994 | 0.83 | XIAP (0.49) | XIAPELANEMLX | |
| SCHEMBL23260256 | 0.82 | XIAP (0.55) | XIAP | |
| SCHEMBL31202557 | 0.82 | XIAP (0.55) | XIAP | |
| SCHEMBL31202564 | 0.82 | XIAP (0.55) | XIAP | |
| SCHEMBL29615598 | 0.82 | XIAP (0.55) | XIAP | |
| SCHEMBL13380009 | 0.82 | XIAP (0.47) | XIAPELANEMLX | |
| SCHEMBL13393694 | 0.82 | XIAP (0.51) | XIAPELANEMLXPOLB | |
| SCHEMBL13380001 | 0.82 | XIAP (0.51) | XIAPELANEMLXPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240083846-A1 | SMAC MIMETICS FOR TREATMENT OF CANCER, PROCESS FOR PREPARATION AND PHARMACEUTICAL COMPOSITION THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2024-03-14 | — | — | US | disclosed |
| US-11590197-B2 | Agents targeting inhibitor of apoptosis proteins | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240083846-A1 | SMAC MIMETICS FOR TREATMENT OF CANCER, PROCESS FOR PREPARATION AND PHARMACEUTICAL COMPOSITION THEREOF | BIRC5, BIRC2, BIRC3 | XIAP 6/4885ELANE 3280/4885CAPN1 3598/4885 |
| US-11590197-B2 | Agents targeting inhibitor of apoptosis proteins | XIAP, BIRC2, BIRC5 | XIAP 1/4885ELANE 1430/4885CAPN1 766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.